申请人:Martin-Luther-Universität Halle-Wittenberg
公开号:EP4008717A3
公开(公告)日:2022-09-07
The presented invention provides compounds of formula (I) and (VIII),
or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R1, R2, W, X, Y, Z, m, n and o are as defined herein. Said compounds of formula (I) are inhibitors of insulin-like growth factor 2 mRNA binding proteins (IGF2BP). Provided are novel inhibitors of IGF2BPs and processes for manufacturing the same. Efficacy of the new compounds is shown in solid cancer models.
所提供的发明提供了式(I)和(VIII)的化合物,或其药学上可接受的盐、溶剂或多晶形式,包括其所有互变异构体和立体异构体,其中R1,R2,W,X,Y,Z,m,n和o如本文所定义。式(I)的这些化合物是胰岛素样生长因子2 mRNA结合蛋白(IGF2BP)的抑制剂。提供了IGF2BP的新型抑制剂和其制造过程。新化合物的功效在实体癌模型中得到了证明。